Bioaffinity Technologies, Inc. (BIAFW) Stock Price & Analysis

Bioaffinity Technologies, Inc. (BIAFW) fell 0.26% to USD 0.16 as of June 10, 2026 at 02:36 UTC, according to Nexqual real-time market data.

BIAFW last closed at USD 0.16; the session ranged USD 0.16–0.16 on volume of 377 shares. Market capitalization is —, with a 52-week range of USD 0.16–0.16 (NCM). Source: Nexqual, June 10, 2026 at 02:36 UTC.

Key Statistics (as of June 10, 2026 at 02:36 UTC)

Technical Analysis (BIAFW)

Nexqual's technical model rates BIAFW "NEUTRAL" based on 3 bullish and 4 bearish signals across 66 daily candles, as of June 10, 2026 at 02:36 UTC.

Analyst Ratings (BIAFW)

Wall Street analysts rate BIAFW "None", per Nexqual as of June 10, 2026 at 02:36 UTC.

Earnings (BIAFW)

Source: Nexqual, June 10, 2026 at 02:36 UTC.

Financials & Fundamentals (BIAFW)

Source: Nexqual, June 10, 2026 at 02:36 UTC.

Financial Health Score (BIAFW)

Nexqual rates Bioaffinity Technologies, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:36 UTC.

Ownership (BIAFW)

Source: Nexqual, June 10, 2026 at 02:36 UTC.

Leadership (BIAFW)

Bioaffinity Technologies, Inc. is led by Maria Zannes (age 69), Founder, President, CEO & Director, per Nexqual as of June 10, 2026 at 02:36 UTC.

Major Backers & Investors (BIAFW)

Notable institutional backers of Bioaffinity Technologies, Inc. include Clear Street Group Inc., UBS Group AG, Citadel, according to Nexqual as of June 10, 2026 at 02:36 UTC.

Active Investors

Source: Nexqual, June 10, 2026 at 02:36 UTC.

From Bioaffinity Technologies, Inc.'s Latest SEC 10-K Filing (filed 2026-03-16)

Key Strengths & Strategy (as disclosed to the SEC)

• The confidentiality agreements are designed to protect our proprietary information, and the invention assignment agreements are designed to gain company control and ownership of technologies that are developed for us by our employees, consultants, or other third parties.
• Although we take steps to protect our proprietary information, including restricting access to our premises and our confidential information, as well as entering into agreements with our employees, consultants, advisors, and potential collaborators, third parties may independently develop the same or similar proprietary information or may otherwise gain access to our proprietary information.
• We intend to seek strategic partners to develop our therapeutic discoveries which could result in broad-spectrum cancer treatments in the future.   Research and optimization of our platform technologies are conducted in laboratories at our wholly owned subsidiary PPLS and leased laboratory space at The University of Texas at San Antonio (UTSA).
• Our approach allows the entire sputum sample to be rapidly analyzed.

Partnerships

• The Current Procedural Terminology ("CPT") Proprietary Laboratory Analysis ("PLA") code specifically for use with CyPath ® Lung, is 0406U with the descriptor "Oncology (lung), flow cytometry, sputum, 5 markers (meso-tetra [\4- carboxyphenyl porphyrin TCPP, CD206, onveniCD66b, CD3, CD19), algorithm reported as likelihood of lung cancer."   We have an agreement with Cardinal Health for logistical services assisting in the delivery of collection kits and return of patient samples to PPLS.
• The CyPath ® Lung study with BAMC will explore an approach that could expand the utility of bronchoscopy-collected samples for earlier, noninvasive lung cancer detection.   In the first quarter of 2026, we began a research collaboration with BAMC to advance the development of companion diagnostic tests targeted at asthma and COPD.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:36 UTC. This page is informational and not investment advice.